Clinical Trials

117 enrolled

Lung Neoplasms

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05980000 2026-03-31

Rambro2

37 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

105 enrolled

Tumor-Agnostic

Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

23 enrolled 12 charts

Stomach Neoplasms

NCT07098338 2026-02-05

LIBRA

278 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

56 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03527108 2026-01-14

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04332367 2026-01-07

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

59 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

37 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT04205968 2025-11-05

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

94 enrolled

Metastatic Small Intestinal Adenocarcinoma

NCT03694002 2025-10-30

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

21 enrolled 17 charts

Thymoma

NCT03909334 2025-10-20

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05071053 2025-08-22

CARMEN-GC01

35 enrolled 14 charts

Adenocarcinoma Gastric

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

309 enrolled 22 charts

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

146 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04069273 2025-07-31

SEQUEL

58 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02678182 2025-06-10

PLATFORM

494 enrolled

Adenocarcinoma of the Oesophagus

NCT04394624 2025-06-06

CARMEN-LC04

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05311176 2025-05-11

nextHERIZON

7 enrolled 8 charts

Stomach Neoplasms

NCT03560973 2025-03-13

RAMES

Other solid neoplasmThoracic

164 enrolled

Mesothelioma

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

43 enrolled 11 charts

Endocrine

Carcinoid Tumor

NCT02581215 2025-01-01

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

84 enrolled 12 charts

Pancreatic Neoplasms

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

166 enrolled 21 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06564298 2024-08-28

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

39 enrolled

Stomach Neoplasms

NCT03689855 2024-07-30

RamAtezo-1

21 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03760822 2024-07-08

SOCRATE

112 enrolled

Stomach Neoplasms

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

60 enrolled

Neoplasm Metastasis, Thymoma

NCT03502746 2024-05-14

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Other solid neoplasmThoracic

34 enrolled 11 charts

Mesothelioma, Malignant

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

116 enrolled

Clinical Stage III Gastric Cancer AJCC v8

NCT01079780 2023-06-28

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

136 enrolled 13 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02520141 2023-06-15

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

61 enrolled 9 charts

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03762564 2022-12-08

RAMOS

21 enrolled

Esophageal Squamous Cell Carcinoma

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

80 enrolled

HER2-positive Gastric Cancer

NCT02317991 2022-07-01

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

65 enrolled 11 charts

Gastroesophageal Cancer

NCT03904108 2022-05-26

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

3 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT04040361 2022-04-06

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Phase 2 Unknown

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04632459 2022-03-11

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Phase 2 Unknown

35 enrolled

Stomach Neoplasms

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

48 enrolled 17 charts

Other solid neoplasm

Malignant Solid Tumor

NCT04179110 2022-02-22

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Phase 2 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

80 enrolled 14 charts

Tumor-Agnostic

Adenocarcinoma

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

204 enrolled 27 charts

Carcinoma, Hepatocellular

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Withdrawn

Lung Neoplasms

NCT02730247 2020-11-19

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

7 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02443883 2020-06-29

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

164 enrolled 13 charts

Stomach Neoplasms

NCT02514551 2020-06-17

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

245 enrolled 17 charts